ADCT
ADC Therapeutics·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
MACD Death Cross
Ample Liquidity
High Gross Profit Margin
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ADCT
Adc Therapeutics Sa
A Swiss-based biotech company that develops antibody-drug conjugates for cancer treatment
Pharmaceutical
06/06/2011
05/15/2020
New York Stock Exchange
263
12-31
Common stock
Biopole, Route de la Corniche 3B, 1066 Epalinges, Switzerland
--
ADC Therapeutics SA was incorporated under the laws of Switzerland on June 6, 2011. The company is a fully integrated commercial-stage biotechnology company that helps improve the lives of cancer patients with next-generation targeted antibody-drug conjugates. The company's flagship product, ZYNLONTA (loncastuximab tesirine or Lonca), received accelerated approval from the FDA on April 23, 2021 and was launched in the United States shortly thereafter for the treatment of adult patients with relapsed or refractory large B-cell lymphoma treated with two or more systems, Including diffuse large B-cell lymphoma not otherwise described, DLBCL caused by low-grade lymphoma, and high-grade B-cell lymphoma. The company's goal is to establish ZYNLONTA as the third-line + DLBCL standard of care, while exploring the application of ZYNLONTA in early treatment and combination to expand market opportunities.
Earnings Call
Q1/2025
Estimate EPS--
Actual EPS-0.22
Estimate Revenue17.71M
Actual Revenue23.03M
ADC Therapeutics Q1 2025: Navigating Contradictions in LOTIS-5 Data and ZYNLONTA's Market Position
May 20,2025 05:39
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS-0.25
Estimate Revenue17.86M
Actual Revenue18.84M
Contradiction Alert: Navigating LOTIS-7's Regulatory Path and ADCETRIS Market Impact in Recent Earnings Call
Aug 12,2025 11:41
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ADCT has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.36, beating expectations. The chart below visualizes how ADCT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ADCT has released its 2025 Q3 earnings report, with revenue of 16.43M, reflecting a YoY change of -11.03%, and net profit of -40.97M, showing a YoY change of 6.83%. The Sankey diagram below clearly presents ADCT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
